BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 29
• 30

• Press Releases

  Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

  December 3, 2025

   · 

  5 min read
• Press Releases

  ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

  December 3, 2025

   · 

  11 min read
• Press Releases

  Drug Discovery Market Set to Reach USD 174.14 Billion by 2035 Driven by AI-Powered Innovation

  December 3, 2025

   · 

  1 min read
• Press Releases

  Cell And Gene Therapy Clinical Trials Market Accelerates from USD 12.47 Billion in 2025 to USD 45.31 Billion by 2034

  December 3, 2025

   · 

  1 min read
• Press Releases

  U.S. Bispecific Antibody Market to Worth USD 448.62 Billion by 2035

  December 3, 2025

   · 

  1 min read
• 

  Alzheimer’s disease

  BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study

  Analysts had noted “unease” from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment would be a “significant development.”

  December 3, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

  December 3, 2025

   · 

  3 min read
• Press Releases

  Kestra Medical Technologies, Ltd. to Report Second Quarter Fiscal 2026 Financial Results

  December 3, 2025

   · 

  1 min read
• Press Releases

  Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

  December 3, 2025

   · 

  7 min read
• Press Releases

  Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

  December 3, 2025

   · 

  5 min read